Advertisement
Advertisement
KYMR
Kymera Therapeutics, Inc. Common Stock
78.25
USDSponsored
-1.93
-2.41%
Mar 27, 16:00 UTC -4
Closed
After-Market
80.33
+2.08
+2.66%
KYMR Earnings Reports
Positive Surprise Ratio
KYMR beat 6 of 22 last estimates.
27%
Next Report
Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
$8.53M
/-$0.89
Implied change from Q4 25 (Revenue/ EPS)
+197.06%
/-8.25%
Implied change from Q1 25 (Revenue/ EPS)
-61.41%
/+8.54%
Kymera Therapeutics, Inc. Common Stock earnings per share and revenue
On Feb 26, 2026, KYMR reported earnings of -0.97 USD per share (EPS) for Q4 25, missing the estimate of -0.81 USD, resulting in a -19.43% surprise. Revenue reached 2.87 million, compared to an expected 15.35 million, with a -81.30% difference. The market reacted with a +4.80% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -0.89 USD, with revenue projected to reach 8.53 million USD, implying an decrease of -8.25% EPS, and increase of 197.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Humacyte, Inc. Common Stock
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.13
Surprise
+3.20%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Entera Bio Ltd. Ordinary Shares
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.07
Surprise
+23.75%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Kymera Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Kymera Therapeutics, Inc. Common Stock reported EPS of -$0.97, missing estimates by -19.43%, and revenue of $2.87M, -81.3% below expectations.
How did the market react to Kymera Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 4.8%, changed from $90.68 before the earnings release to $95.03 the day after.
When is Kymera Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for Kymera Therapeutics, Inc. Common Stock's next earnings report?
Based on 13
analysts, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$0.89 and revenue of $8.53M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement